MeritValue

Shuttle Pharmaceuticals Holdings, Inc.

SHPHdata completeness 63%5 fiscal years on file

Data notes: no data for concept 'revenue'; no data for concept 'incomeTaxExpense'

The thesis, from the filings

Shuttle Pharmaceuticals Holdings, Inc. earns about -509% on equity, and has bought back 82% of its shares over 5 years. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.

i. The business — what you’d actually own
FigureFY 2021FY 2022FY 2023FY 2024FY 2025
Revenue—————
Net income−$1.15M1−$5M2−$6.59M3−$9.14M4−$11.7M4
Operating cash flow−$300,3365−$2.67M6−$5.58M7−$7.33M8−$9.48M8
Capital expenditure——$19,0469——
Free cash flow (derived)——−$5.6M7——
Total debt$91,02110————
Cash & equivalents$504,74911$8.42M12$2.58M13$1.92M14$334,00514
Diluted shares9.3M1.3M1.9M115,4931.6M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
$13.76
your share of equity
Profit it earned you last year
−$71.56
Free cash flow it threw off
—
Debt you’d be carrying
—

10 shares is a claim on $13.76 of net worth that earned you −$71.56 last year.

iii. Is this a good business?
Moat signal · return on equity
-509% avg · 5y
FY21 —FY22 -65%FY23 -163%FY24 -1290%FY25 -520%

It earned an average -509% on equity over 5 years. Compare that to what it costs to fund the business.

seeing a moat in the numbers →
Management signal · capital allocation
−82% shares · 5y

Share count is down 82% over 5 years — management has been buying back stock, quietly handing owners a bigger slice. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.1.0
DCF · Growth Exit 10Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
DCF · Growth Exit 5Y
not applicable
only 1 years of FCF (need ≥3) — model not applicable
Earnings Power Value
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
Graham Number
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Sources — the receipts
  1. 10-K · period ending 2021-12-31 · accession 0001493152-23-007686 (NetIncomeLoss)
  2. 10-K/A · period ending 2022-12-31 · accession 0001493152-24-034898 (NetIncomeLoss)
  3. 10-K · period ending 2023-12-31 · accession 0001493152-25-008300 (NetIncomeLoss)
  4. 10-K · period ending 2024-12-31 · accession 0001493152-26-014131 (NetIncomeLoss)
  5. 10-K · period ending 2021-12-31 · accession 0001493152-23-007686 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K/A · period ending 2022-12-31 · accession 0001493152-24-034898 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K · period ending 2023-12-31 · accession 0001493152-25-008300 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K · period ending 2024-12-31 · accession 0001493152-26-014131 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K · period ending 2023-12-31 · accession 0001493152-25-008300 (PaymentsToAcquirePropertyPlantAndEquipment)
  10. 10-K · period ending 2021-12-31 · accession 0001493152-23-007686 (LongTermDebt)
  11. 10-K · period ending 2021-12-31 · accession 0001493152-23-007686 (CashAndCashEquivalentsAtCarryingValue)
  12. 10-K/A · period ending 2022-12-31 · accession 0001493152-24-034898 (CashAndCashEquivalentsAtCarryingValue)
  13. 10-K · period ending 2023-12-31 · accession 0001493152-25-008300 (CashAndCashEquivalentsAtCarryingValue)
  14. 10-K · period ending 2024-12-31 · accession 0001493152-26-014131 (CashAndCashEquivalentsAtCarryingValue)